In the 2010 summary, Gen Re included NACII
survey data from 38 direct writers of critical illness insurance.
Meanwhile, CI sales grew modestly in 2004 and 2005, according to NACII
research, and CI premium held steady at approximately $130 million.
Note: AFLAC participated in the NACII
survey; however, its product represented a specified disease policy with a limited CI benefit, so the data was separated out.
study noted that AFLAC's worksite health product provides a limited CI cancer rider, paying a $5,000 lump sum on first occurrence and $2,500 on reoccurrence.